# LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/lba14-amivantamab-plus-lazertinib-vs-osimertinib-as-first-line-treatment-in/

## Facts

| Field | Value |
| --- | --- |
| Author Names | B.C. Cho,Enriqueta Felip,Alexander I. Spira,Nicolas Girard,Jin Sun Lee,SH Lee,Y.V. Ostapenko,Pongwut Danchaivijitr,B. Liu,Adlinda Alip,Ernesto Korbenfeld,Josiane Mourão Dias,Tao Sun,Melissa Martínez,Joshua Bauml,Martin Shreeve,Seema Sethi,Roland E. Knoblauch,Hidetoshi Hayashi,Shun Lü |
| Citations | 83 |
| DOI | 10.1016/j.annonc.2023.10.062 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | http://www.annalsofoncology.org/article/S0923753423042060/pdf |
| OpenAlex ID | https://openalex.org/W4387809613 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Adlinda Alip](https://scholariq.org/researchers/adlinda-alip/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer therapeutics and mechanisms](https://scholariq.org/topics/cancer-therapeutics-and-mechanisms/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.